



Sara Tufi


HILIC coupled to mass spectrometry for targeted and non-targeted metabolomics

Marja Lamoree

Why metabolomics for environmental quality assessment?

Limitations of (in vitro) bioassays:

- > Focus on one specific endpoint
- > Limited sensitivity



Metabolomics

- ❖ Focus on multiple endpoints (metabolites or sets of metabolites) simultaneously
- ❖ Includes *in-vivo* metabolism



Metabolomics


Aim: study sub-lethal neurotoxic effects in non-target invertebrate species

- Non-targeted metabolomics: method development to investigate changes in (non-target) hydrophilic and hydrophobic metabolites
- Targeted metabolomics: method development for neurotransmitter profiling of *L. stagnalis*
- Apply both approaches to snails exposed to
 - i) imidacloprid
 - ii) a surface water extract



Background - Imidacloprid

- Neonicotinoids - novel generation of neuro-active insecticides
- High water solubility (610 mg/L in 20°C H₂O; log K_{ow} = 0.57)
- High environmental occurrence
- Neonicotinoid insecticides probably affect postsynaptic receptors (nAChRs)
- Evidence of a connection to honey bee colony collapse
- EU imposed a number of (temporary) use restrictions in greenhouses
- Low affinity for the nAChRs of mammals has been shown, but what for invertebrates and aquatic species?




Macro-Invertebrate Decline in Surface Water Polluted with Imidacloprid

Tessa C. Van Dijk, Marja A. Van Staalduinen, Jeroen P. Van der Sluijs*

PLOSone 2013

Lymnaea stagnalis organ dissection



Sample pretreatment:
Snap freezing in liquid nitrogen to quench the metabolic activity

16 week old snails,
± 2.85 cm shell length


Metabolomics workflow




Study design



Extraction of metabolites








Chemical analysis




Metabolite screening/identification

Data analysis

Biological interpretation




Sample preparation




- A tissue normalization step was included to normalize data
- A mix of internal standards of different metabolite classes was added to normalize the signal intensities and to align retention times

Analytical strategy



Lymnaea stagnalis
central nervous system



Samples

SNAIL CNS

MeOH/H₂O fraction

Chloroform fraction

EXTRACTION

TARGETED
ANALYSIS
neurotransmitters

NONTARGETED
ANALYSIS
polar
metabolites

NONTARGETED
ANALYSIS
nonpolar
metabolites

ANALYTICAL STRATEGY


LC-QQQ

HILIC - (ESI) TOF

GC - (APCI) TOF

ANALYTICAL METHOD

Metabolic pathways investigated




HILIC, RP-LC and GC analysis

Waters **XBridge Amide** column, 150×2.1 mm, 3.5 μm; Amide guard column 10×2.1mm, 3.5 μm Gradients of ACN/H₂O 30:70 v/v NH₄HCOOH 10 mM (A) and ACN/H₂O 95:5 v/v ammonium acetate 10 mM (B); for **pH 9.0** adjustment with ammonium hydroxide and for **pH 2.8** with HCOOH to pH 2.8. For both LC approaches, the separation occurred at 30 °C, the flow rate was set to 0.25 ml/min, and the injection volume was 5 μL

Waters **C18 Symmetry** column, 150×2.1 mm, 3.5 μm; C18 guard column 10×2.1 mm, 3.5 μm Gradient of H₂O and ACN with 0.1 % formic acid.


GC-APCI Derivatization of chloroform fractions with 500 μl of a methanolic BF₃ solution, kept for 30 min at 80 °C, with subsequent liquid/liquid extraction with hexane

HR-TOF-MS on MICROTOF II, Bruker




Platform performance - metabolome coverage

Hydrophilic and hydrophobic metabolite fractions



















- Each analytical platform has its own specific performance for the different metabolite classes
- HILIC represents an important chromatographic method for polar metabolites

Molecular features



GC-APCI(+)>HILIC-ESI(+)>RPLC-ESI(+)

Targeted analysis of neurotransmitters, precursors and metabolites




HILIC columns tested


Physico-chemical parameters of the HILIC columns tested evaluated using a ToF-MS.

Column	Provider	Functionality/Support	Size (mm)	Particle size (μm)
XBridge HILIC	Waters	Silica/Silica	4.6×100	2.5
XBridge Amide	Waters	Amide/Silica	2.1×100	3.5
TSKgel Amide-80	Tosoh	Amide/Silica	2.0×100	5
Asahipak NH2P-50 2D	Shodex	Amino/Polyvinyl alcohol Amino	2.0×150	5
ZIC-cHILIC	Merck-Sequant	Zwitterionic/Silica	2.1×150	3
ZIC-pHILIC	Merck-Sequant	Zwitterionic/Polymeric	2.1×150	5


Separation factor k (log₂) distribution



Heat map and hierarchical clustering analysis of peak areas



HILIC-QqQ chromatogram of 20 neurotransmitters, precursors and metabolites




0.3 ml/min; gradient of 100% H₂O and 90:10 ACN:H₂O (v/v)

Method validation parameters

Analyte	Labeled IS	RT	RSD %; RT Intraday	RSD %; RT Interday	Linear range (ng/mL)	R ²	LOD (ng/mL)	LOQ (ng/mL)	R %	RSD % Method
3-MT	3-MT-d ₄	7.7	1.0	6.2	5–3000	0.996	1.11	3.3	95	2.2
5-HIAA	5-HIAA-d ₅	3.4	1.6	4.1	10–2500	0.990	3.85	12	90	2.3
5-Hydroxy-L-tryptophan	5-Hydroxy-L-tryptophan-d ₄	12.2	1.0	2.6	20–3000	0.975	3.68	11	73	6.8
Acetylcholine	Acetylcholine-d ₄	3.0	0.5	4.8	0.05–1000	0.998	0.02	0.1	92	1.1
Choline	Choline-d ₁₃	6.3	0.9	5.4	1–1000	0.990	0.35	1.0	85	2.1
L-DOPA	DOPA-d ₃	13.3	0.5	4.7	100–3000	0.902	19.5	58	84	9.4
Dopamine	Dopamine-d ₄	11.4	0.4	3.8	20–2500	0.995	5.50	17	86	2.7
Epinephrine	Epinephrine- ¹³ C ₂ ¹⁵ N	11.6	0.3	4.4	20–2500	0.986	5.56	17	87	3.3
GABA	GABA-d ₆	12.1	0.3	3.5	40–3000	0.979	19.3	58	81	4.2
Glutamate	Glutamate-d ₅	13.6	0.8	2.2	20–3000	0.960	2.47	7.4	63	18
Glutamine	Glutamine- ¹³ C ¹⁵ N	13.3	0.3	2.5	5–3000	0.942	1.51	4.5	79	1.7
Histamine	L-Tryptophan-d ₃	18.3	0.5	1.5	100–3000	0.973	25.2	76	89	1.7
Histidine	L-Tryptophan-d ₃	15.8	0.4	2.5	20–400	0.930	0.31	0.9	89	1.7
L-Tryptophan	L-Tryptophan-d ₃	10.7	0.4	3.2	5–2500	0.993	0.54	1.6	89	1.7
L-Tyrosine	L-Tyrosine-d ₄	12.1	0.5	3.2	40–3000	0.948	8.22	25	72	3.0
Norepinephrine	Norepinephrine-d ₆	12.7	0.5	4.2	40–2500	0.942	13.2	40	89	4.2
Normetanephrine	Norepinephrine-d ₆	10.7	0.2	3.6	1–1000	0.995	0.28	0.9	89	4.2
Phenylalanine	Epinephrine- ¹³ C ₂ ¹⁵ N	10.3	1.0	3.2	0.1–1500	0.988	0.03	0.1	87	3.3
Serotonin	Serotonin-d ₄	10.5	0.8	3.9	0.5–2500	0.994	0.10	0.3	89	1.6
Tyramine	3-MT-d ₄	9.7	0.5	4.8	1–1000	0.997	0.35	1.0	95	2.2

Exposure to imidacloprid



10 DAYS
CTRL GROUP
0.1 µg/L
1 µg/L
10 µg/L
100 µg/L

Conditioning period of 2 days for adaptation
 Refreshing and egg counting every second day

Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9	Day 10	Day 11	Day 12	Day 13	Day 14
Selection	Condition	Condition	Exposure	Exposure	Exposure	Exposure	Exposure	Exposure	Exposure	Exposure	Exposure	Exposure	Dissection
			Egg counting		Egg counting		Egg counting		Egg counting		Egg counting		Egg counting
Food			Food		Food		Food		Food		Food		Food
Refreshing			Refreshing		Refreshing		Refreshing		Refreshing		Refreshing		Refreshing

Data analysis workflow

IMI 0.1


- Metabolic changes visible at low, environmentally relevant concentrations
- Indication of inflammation and neuron cell injury
- Involvement of the cholinergic system, possibly through an increase in cholinergic gene expression
- Indication of GABA receptor antagonist activity
- Insight in the involvement of different or unexpected metabolic pathways

● Down-regulated
● Up-regulated
● Not-detected

Acknowledgment

More info: sara.tufi@vu.nl
marja.lamoree@vu.nl

- Victoria Osorio Torrens and the EDA-EMERGE network
- Pim Leonards
- Jacob de Boer



THANK YOU

